share_log

GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Delivers Shareholders Respectable 11% CAGR Over 3 Years, Surging 7.0% in the Last Week Alone

GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Delivers Shareholders Respectable 11% CAGR Over 3 Years, Surging 7.0% in the Last Week Alone

光裕源中草药(上海证券交易所代码:600771)在3年内为股东带来了可观的11%的复合年增长率,仅在上周就飙升了7.0%
Simply Wall St ·  02/07 17:21

It hasn't been the best quarter for GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders, since the share price has fallen 13% in that time. But over three years, the returns would have left most investors smiling In fact, the company's share price bested the return of its market index in that time, posting a gain of 38%.

对于广裕源中药材有限公司(SHSE: 600771)股东来说,这并不是最好的季度,因为当时股价已经下跌了13%。但是在三年内,回报会让大多数投资者微笑。实际上,该公司的股价超过了当时的市场指数回报率,涨幅为38%。

Since it's been a strong week for GuangYuYuan Chinese Herbal Medicine shareholders, let's have a look at trend of the longer term fundamentals.

由于对光裕源中药股东来说,这是强劲的一周,让我们来看看长期基本面的走势。

Given that GuangYuYuan Chinese Herbal Medicine didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

鉴于光裕源中草药在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。当一家公司没有盈利时,我们通常预计收入会有良好的增长。这是因为快速的收入增长可以很容易地推断出来预测利润,通常规模相当大。

In the last 3 years GuangYuYuan Chinese Herbal Medicine saw its revenue grow at 2.1% per year. That's not a very high growth rate considering it doesn't make profits. The modest growth is probably broadly reflected in the share price, which is up 11%, per year over 3 years. The real question is when the business will generate profits, and how quickly they will grow. Given the market doesn't seem too excited about the stock, a closer look at the financial data could pay off, if you can find indications of a stronger growth trend in the future.

在过去的3年中,光裕源中药的收入以每年2.1%的速度增长。考虑到它没有盈利,这不是一个很高的增长率。这种温和的增长可能广泛反映在股价上,股价在3年内每年上涨11%。真正的问题是企业何时会产生利润,以及它们将以多快的速度增长。鉴于市场似乎对该股并不太兴奋,如果你能发现未来增长趋势更强劲的迹象,仔细研究财务数据可能会得到回报。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。

earnings-and-revenue-growth
SHSE:600771 Earnings and Revenue Growth February 7th 2024
SHSE: 600771 2024 年 2 月 7 日收益和收入增长

If you are thinking of buying or selling GuangYuYuan Chinese Herbal Medicine stock, you should check out this FREE detailed report on its balance sheet.

如果您正在考虑买入或卖出光裕源中草药股票,则应在其资产负债表上查看这份免费的详细报告。

A Different Perspective

不同的视角

While the broader market lost about 24% in the twelve months, GuangYuYuan Chinese Herbal Medicine shareholders did even worse, losing 29%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - GuangYuYuan Chinese Herbal Medicine has 1 warning sign we think you should be aware of.

尽管整个市场在十二个月中下跌了约24%,但光裕源中药股东的表现甚至更糟,跌幅为29%。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。好的一面是,长期股东赚了钱,在过去的五年中,每年增长6%。最近的抛售可能是一个机会,因此可能值得查看基本面数据以寻找长期增长趋势的迹象。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。例如,冒险吧——光裕源中草药有 1 个我们认为你应该注意的警告信号。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想与管理层一起购买股票,那么你可能会喜欢这份免费的公司名单。(提示:业内人士一直在购买它们)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发